Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Ophthalmic Surgical

This excerpt taken from the EYE 8-K filed Jul 20, 2005.

Ophthalmic Surgical

 

Ophthalmic surgical revenue grew 66.2 percent in the second quarter, including a 3.7 percent increase related to foreign currency, to $144.0 million, compared to $86.7 million in the year-ago quarter. The increase included the addition of the VISX business in the last four weeks of the quarter, the impact of the Pfizer surgical ophthalmic business acquired in the third quarter of 2004 and continuing acceptance of the company’s branded surgical products.

 

Total intraocular lens (IOL) sales rose 19.9 percent to $66.9 million, compared to $55.8 million in the second quarter of 2004. The increase reflected primarily the acquisition of the Pfizer ophthalmic surgical business and the strength of the company’s promoted IOL technologies, the Tecnis® and Sensar® lenses.

 

Sales of viscoelastics rose to $36.1 million, compared to $4.6 million one year ago. This rise reflected primarily the addition of the Healon® family of viscoelastics, which AMO acquired as part of the Pfizer transaction.

 

Sales of phacoemulsification products grew 2.5 percent during the quarter to $20.3 million, compared to $19.8 million one year ago. The company’s proprietary Sovereign® system with WhiteStar™ technology was a key contributor to sales performance in the quarter.

AMO Announces Second Quarter 2005 Results – Page 3

 

Laser vision correction revenue was $13.4 million in the second quarter, reflecting the approximate four-week period that AMO owned the VISX business. Of this amount, approximately 73 percent was derived from licensing revenue, with the remainder from system sales and service.

 

This excerpt taken from the EYE 8-K filed Apr 28, 2005.

Ophthalmic Surgical

 

Ophthalmic surgical revenue grew 51.6 percent in the first quarter, including a 4.2 percent increase related to foreign currency, to $118.7 million, compared to $78.3 million in the year-ago quarter.

 

Total intraocular lens (IOL) sales rose 17.2 percent to $60.5 million, compared to $51.6 million in the first quarter of 2004. The increase reflects primarily the acquisition of the Pfizer ophthalmic surgical business and the strength of the company’s promoted IOL technologies, the Tecnis® and Sensar® lenses.

 

Sales of viscoelastics rose to $32.6 million, compared to $4.2 million one year ago. This rise reflected the addition of the Healon® family of viscoelastics, which AMO acquired as part of the Pfizer transaction, as well as continued growth of AMO’s existing Vitrax® brand.

 

Sales of phacoemulsification products grew 5.2 percent during the quarter to $18.5 million, compared to $17.6 million one year ago. Growth was led by the company’s Sovereign® Compact™ system with WhiteStar™ technology.

 

This excerpt taken from the EYE 8-K filed Apr 7, 2005.

Ophthalmic Surgical

 

Ophthalmic surgical revenue grew 56.0 percent in the fourth quarter, including a 5.9 percent increase related to foreign currency, to $135.0 million, compared to $86.5 million in the year-ago quarter. Quarterly highlights included:

 

•   Total intraocular lens (IOL) sales rose 20.2 percent to $68.4 million, compared to $56.9 million in the fourth quarter of 2003. The increase reflects primarily the acquisition of the Pfizer ophthalmic surgical business and the strength of the company’s promoted IOL technologies, the Tecnis® and Sensar® lenses. The Tecnis® lens, which AMO acquired as part of the Pfizer ophthalmic surgical acquisition, has a proprietary modified prolate design that reduces spherical aberrations and improves contrast sensitivity. It is the only lens on the market with a unique FDA claim for improved functional vision. The Sensar® lens is AMO’s top selling IOL with a patented edge design to reduce halos, glare and the incidence of posterior capsular opacification.

 

•   Sales of viscoelastics rose more than nine-fold during the quarter to $37.1 million, compared to $4.0 million one year ago. This rise reflected the addition of the Healon® family of viscoelastics, which AMO acquired as part of the Pfizer transaction, as well as continued growth of AMO’s existing Vitrax® brand.

 

•   Sales of phacoemulsification products grew 4.4 percent during the quarter to $20.9 million, compared to $20.0 million one year ago. Growth was led by the company’s Sovereign® Compact™ system with WhiteStar™ technology, as well as recurring revenue from the consumable surgical packs used during every phacoemulsification procedure performed with an AMO machine.

 

For the full year 2004, ophthalmic surgical revenue grew 34.9 percent, including a 6.3 percent increase related to foreign currency, to $413.4 million, compared to $306.5 million in 2003.

 

- more -

This excerpt taken from the EYE 8-K filed Feb 14, 2005.

Ophthalmic Surgical

 

Ophthalmic surgical revenue grew 56.0 percent in the fourth quarter, including a 5.9 percent increase related to foreign currency, to $135.0 million, compared to $86.5 million in the year-ago quarter. Quarterly highlights included:

 

•   Total intraocular lens (IOL) sales rose 20.2 percent to $68.4 million, compared to $56.9 million in the fourth quarter of 2003. The increase reflects primarily the acquisition of the Pfizer ophthalmic surgical business and the strength of the company’s promoted IOL technologies, the Tecnis® and Sensar® lenses. The Tecnis® lens, which AMO acquired as part of the Pfizer ophthalmic surgical acquisition, has a proprietary modified prolate design that reduces spherical aberrations and improves contrast sensitivity. It is the only lens on the market with a unique FDA claim for improved functional vision. The Sensar® lens is AMO’s top selling IOL with a patented edge design to reduce halos, glare and the incidence of posterior capsular opacification.

 

•   Sales of viscoelastics rose more than nine-fold during the quarter to $37.1 million, compared to $4.0 million one year ago. This rise reflected the addition of the Healon® family of viscoelastics, which AMO acquired as part of the Pfizer transaction, as well as continued growth of AMO’s existing Vitrax® brand.

 

•   Sales of phacoemulsification products grew 4.4 percent during the quarter to $20.9 million, compared to $20.0 million one year ago. Growth was led by the company’s Sovereign® Compact™ system with WhiteStar™ technology, as well as recurring revenue from the consumable surgical packs used during every phacoemulsification procedure performed with an AMO machine.

 

- more -

For the full year 2004, ophthalmic surgical revenue grew 34.9 percent, including a 6.3 percent increase related to foreign currency, to $413.4 million, compared to $306.5 million in 2003.

 

This excerpt taken from the EYE 8-K filed Feb 8, 2005.

Ophthalmic Surgical

 

Ophthalmic surgical revenue grew 56.0 percent in the fourth quarter, including a 5.9 percent increase related to foreign currency, to $135.0 million, compared to $86.5 million in the year-ago quarter. Quarterly highlights included:

 

•   Total intraocular lens (IOL) sales rose 20.2 percent to $68.4 million, compared to $56.9 million in the fourth quarter of 2003. The increase reflects primarily the acquisition of the Pfizer ophthalmic surgical business and the strength of the company’s promoted IOL technologies, the Tecnis® and Sensar® lenses. The Tecnis® lens, which AMO acquired as part of the Pfizer ophthalmic surgical acquisition, has a proprietary modified prolate design that reduces spherical aberrations and improves contrast sensitivity. It is the only lens on the market with a unique FDA claim for improved functional vision. The Sensar® lens is AMO’s top selling IOL with a patented edge design to reduce halos, glare and the incidence of posterior capsular opacification.

 

•   Sales of viscoelastics rose more than nine-fold during the quarter to $37.1 million, compared to $4.0 million one year ago. This rise reflected the addition of the Healon® family of viscoelastics, which AMO acquired as part of the Pfizer transaction, as well as continued growth of AMO’s existing Vitrax® brand.

 

•   Sales of phacoemulsification products grew 4.4 percent during the quarter to $20.9 million, compared to $20.0 million one year ago. Growth was led by the company’s Sovereign® Compact™ system with WhiteStar™ technology, as well as recurring revenue from the consumable surgical packs used during every phacoemulsification procedure performed with an AMO machine.

 

- more -

AMO Announces Fourth Quarter and Year-End Results – Page 3

 

For the full year 2004, ophthalmic surgical revenue grew 34.9 percent, including a 6.3 percent increase related to foreign currency, to $413.4 million, compared to $306.5 million in 2003.

 

EXCERPTS ON THIS PAGE:

8-K
Jul 20, 2005
8-K
Apr 28, 2005
8-K
Apr 7, 2005
8-K
Feb 14, 2005
8-K
Feb 8, 2005

RELATED TOPICS for EYE:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki